Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report

Serge Goldman; Dominique Bron; Thomas Tousseyn; Irina Vierasu; Laurent Dewispelaere; Pierre Heimann; Elie Cogan; Michel Goldman

doi:10.3389/fmed.2021.798095

Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report

Front Med (Lausanne). 2021 Nov 25:8:798095. doi: 10.3389/fmed.2021.798095. eCollection 2021.

Authors

Serge Goldman¹, Dominique Bron², Thomas Tousseyn³, Irina Vierasu¹, Laurent Dewispelaere⁴, Pierre Heimann⁴, Elie Cogan⁵, Michel Goldman⁶

Affiliations

¹ Department of Nuclear Medicine, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
² Department of Hematology, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
³ Department of Pathology, UZ Leuven Hospitals, Leuven, Belgium.
⁴ Laboratory of Hematology, LHUB, Université Libre de Bruxelles, Brussels, Belgium.
⁵ Department of Internal Medicine, CHIREC Hospital, Brussels, Belgium.
⁶ I3h Institute, Université Libre de Bruxelles, Brussels, Belgium.

Abstract

Since nucleoside-modified mRNA vaccines strongly activate T follicular helper cells, it is important to explore the possible impact of approved SARS-CoV-2 mRNA vaccines on neoplasms affecting this cell type. Herein, we report and discuss unexpected rapid progression of lymphomatous lesions after administration of a BNT162b2 mRNA vaccine booster in a man recently diagnosed with AITL.

Keywords: COVID-19; T cell; angioimmunoblastic; follicular; lymphoma; mRNA vaccine.

Publication types

Case Reports